Suitability of and tolerance to Iotrolan 300 in bronchography via the fibreoptic bronchoscope.

Abstract

The contrast agent Iotrolan 300 has potential advantages for bronchography over previous agents in that it can be injected directly through the bronchoscope and it does not obscure bronchoscopic vision or interfere with further bronchoscopic procedures. It was used for selective bronchography in 20 patients with suspected bronchiectasis. Side effects and change in FEVy and in arterial oxygen saturation were compared in these patients and in 14 patients undergoing bronchoscopy for suspected carcinoma. Thirteen of the 20 patients undergoing bronchography had side effects, mainly headache, nausea, and a feeling of heat or flushing. The fall in FEVy at four hours (0-3 1) did not differ from the fall in the control group (0'1 1). The fall in arterial oxygen saturation (Sao2) during bronchography (9-4%) did not differ significantly from the fall during bronchoscopy in the control group (6-1%). Iotrolan gave good quality bronchograms, which in all cases provided a diagnosis. Iotrolan appears to be suitable for bronchography by fibreoptic bronchoscope and to be well tolerated. Department of

Bronchoscopic Balloon Dilation (BBD) for Benign Tracheobronchial Stenosis

“…Occasionally the initial inflation times must be very short, but they can be increased as dilation proceeds. Nonionic contrast media are safe for the bronchus because bronchography using nonionic contrast media instead of propylidone is performed safely (Morcos et al, 1989(Morcos et al, , 1990Riebel & Wartner, 1990).…”